Subscribe
m-a-istock-537908812
designer491 / iStockphoto.com
3 April 2018Asia-Pacific

Takeda mulls Shire acquisition bid

Japan-based Takeda has revealed that it is considering plans to acquire biopharmaceutical company Shire.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Asia-Pacific
Takeda makes fourth offer to buy Shire
23 April 2018   Japan-based Takeda has upped its offer to buy Ireland-headquartered Shire for the fourth time, raising its bid to approximately £44 billion.
Biotechnology
Shire to sell oncology business for $2.4bn
17 April 2018   Biotech company Shire has revealed plans to sell its oncology business for $2.4 billion to France-based Servier.
Americas
Shire welcomes Adderall generic ruling
27 March 2018   A US judge handed a win to Shire late last week, finding that a generic version of its attention deficit hyperactivity disorder drug Adderall XR would infringe Shire’s patents.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Asia-Pacific
Takeda makes fourth offer to buy Shire
23 April 2018   Japan-based Takeda has upped its offer to buy Ireland-headquartered Shire for the fourth time, raising its bid to approximately £44 billion.
Biotechnology
Shire to sell oncology business for $2.4bn
17 April 2018   Biotech company Shire has revealed plans to sell its oncology business for $2.4 billion to France-based Servier.
Americas
Shire welcomes Adderall generic ruling
27 March 2018   A US judge handed a win to Shire late last week, finding that a generic version of its attention deficit hyperactivity disorder drug Adderall XR would infringe Shire’s patents.

More on this story

Asia-Pacific
Takeda makes fourth offer to buy Shire
23 April 2018   Japan-based Takeda has upped its offer to buy Ireland-headquartered Shire for the fourth time, raising its bid to approximately £44 billion.
Biotechnology
Shire to sell oncology business for $2.4bn
17 April 2018   Biotech company Shire has revealed plans to sell its oncology business for $2.4 billion to France-based Servier.
Americas
Shire welcomes Adderall generic ruling
27 March 2018   A US judge handed a win to Shire late last week, finding that a generic version of its attention deficit hyperactivity disorder drug Adderall XR would infringe Shire’s patents.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB